Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February.
The Wall Street forecasts fourth-quarter adjusted EPS of $3.35 and sales of $2.40 billion, while fiscal year 2024 adjusted EPS is expected to be $16.34 and sales of $9.64 billion.
In January, the FDA approved the Supplemental marketing application for lecanemab-irmb (Leqembi) intravenous (IV) maintenance dosing once every four weeks.
Leqembi is indicated for Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease. After 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks may be considered or the regimen of 10 mg/kg once every two weeks may be continued.
The FDA and the European Medicines Agency accepted to review supplemental marketing applications seeking approval for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA).
The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and a higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (Spinraza).
Investors are focused on Biogen's growth strategies. This includes expanding its pipeline, pursuing external business development, or leveraging new opportunities to counter declining revenue in the latter half of the decade.
In December, Jefferies downgraded Biogen, citing the company's tough setup.
Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030.
Challenges like PET scan reimbursement, slow protocol updates at major hospital networks, and identifying eligible patients continue to hinder adoption.
Price Action: BIIB stock is down 2.61% at $138.81 at the last check on Tuesday.
Read Next:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
